Entrada Therapeutics, Inc. (TRDA)

13.88 +0.38 (+2.81%) At close: 04:00PM EDT

Entrada Therapeutics, Inc.

One Design Center Place
Suite 17- 500
Boston, MA 02210
United States
(857) 520-9158
https://www.entradatx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 159

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Dipal Doshi	CEO & Director	902.08k	N/A	1976
Mr. Nathan J. Dowden	President & COO	654.6k	N/A	1971
Dr. Natarajan Sethuraman Ph.D.	Chief Scientific Officer	654.6k	N/A	1962
Dr. Jared Cohen J.D., Ph.D.	General Counsel	N/A	N/A	N/A
Ms. Kerry Robert M.S.	Senior Vice President of People	N/A	N/A	N/A
Ms. Karla MacDonald	Chief Corporate Affairs Officer	N/A	N/A	N/A
Mr. Kevin Healy Ph.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Corporate Governance

Entrada Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.